Can-Fite BioPharma Ltd. (CANF) stock
CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.42−0.07 (-4.70%)
Close on Nov 13, 2026Market cap $1.86MP/E –Yield –
Can-Fite BioPharma cash
Cash and short-term investments held at the end of each period.
Can-Fite BioPharma's cash was $2.99M at Jun 30, 2026. For fiscal 2025 it was $5.53M, down 29.9% from the year before. Over ten years it grew -10.6% a year on average. The highest annual figure on record is $16.92M in fiscal 2015.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.53M | -29.9% |
| FY2024 | Dec 31, 2024 | $7.88M | -11.5% |
| FY2023 | Dec 31, 2023 | $8.90M | +198.2% |
| FY2022 | Dec 31, 2022 | $2.99M | -35.5% |
| FY2021 | Dec 31, 2021 | $4.63M | -44.5% |
| FY2020 | Dec 31, 2020 | $8.34M | +202.2% |
| FY2019 | Dec 31, 2019 | $2.76M | -23.6% |
| FY2018 | Dec 31, 2018 | $3.62M | +3.1% |
| FY2017 | Dec 31, 2017 | $3.51M | -56.8% |
| FY2016 | Dec 31, 2016 | $8.12M | -52.0% |
| FY2015 | Dec 31, 2015 | $16.92M | +82.3% |
| FY2014 | Dec 31, 2014 | $9.28M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.99M | -36.7% |
| Q4 FY2025 | Dec 31, 2025 | $5.53M | -37.9% |
| Q2 FY2025 | Jun 30, 2025 | $6.46M | +86.7% |
| Q4 FY2024 | Dec 31, 2024 | $7.88M | +164.0% |
| Q2 FY2024 | Jun 30, 2024 | $4.73M | +176.2% |
| Q4 FY2023 | Dec 31, 2023 | $8.90M | +92.4% |
| Q2 FY2023 | Jun 30, 2023 | $3.46M | -54.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.99M | -64.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.71M | -81.1% |
| Q4 FY2021 | Dec 31, 2021 | $4.63M | +67.6% |
| Q2 FY2021 | Jun 30, 2021 | $7.54M | -8.1% |
| Q4 FY2020 | Dec 31, 2020 | $8.34M | +130.8% |
| Q2 FY2020 | Jun 30, 2020 | $9.06M | +55.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.76M | -21.2% |
| Q2 FY2019 | Jun 30, 2019 | $8.20M | +19.6% |
| Q4 FY2018 | Dec 31, 2018 | $3.62M | -55.5% |
| Q2 FY2018 | Jun 30, 2018 | $5.84M | -65.5% |
| Q4 FY2017 | Dec 31, 2017 | $3.51M | -62.2% |
| Q2 FY2017 | Jun 30, 2017 | $6.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.12M | – |
| Q4 FY2015 | Dec 31, 2015 | $16.92M | – |
| Q4 FY2014 | Dec 31, 2014 | $9.28M | – |
See a number that looks wrong?